Araştırma Makalesi
BibTex RIS Kaynak Göster

Relationship between neutrophil/lymphocyte, platelet/lymphocyte, CRP/Albumin ratio and survival in ovarian cancer

Yıl 2021, Cilt: 14 Sayı: 3, 666 - 674, 01.07.2021
https://doi.org/10.31362/patd.907695

Öz

Kaynakça

  • 1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013;63(1):11–30.
  • 2. Morgan Jr RJ, Armstrong DK, Alvarez RD, et al. Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14(9):1134–63.
  • 3. Holschneider, C.H. and J.S. Berek. Ovarian cancer: epidemiology, biology, and prognostic factors. In seminars in surgical oncology. 2000. Wiley Online Library
  • 4. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol. 2004;191(3):733–740.
  • 5. Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol 2013;25:50–1.
  • 6. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–545.
  • 7. Nie W, Yu T, Sang Y, et al. Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment. Biochem Biophys Res Commun 2017;482:1400–1406.
  • 8. He W, Yin C, Guo G, et al. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol 2013; 30:439.
  • 9. Jung MR, Park YK, Jeong O, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 2011;104:504–10.
  • 10. Liu X, Qu JK, Zhang J, et al. Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: a meta-analysis. Medicine 2017;96:e8101.
  • 11. Gu XB, Tian T, Tian XJ, et al. Prognostic significance of neutrophil-tolymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep 2015;5:12493.
  • 12. Yodying H, Matsuda A, Miyashita M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2016;23:646–654.
  • 13. Baert T, Van Camp J, Vanbrabant L, et al. Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol Oncol 2018;150:31–37.
  • 14. Zhu Y, Zhou S, Liu Y, et al. Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review. BMC Cancer 2018;18:443.
  • 15. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005;117(2):104–111.
  • 16. Hefler LA, Concin N, Hofstetter G, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008;14(3):710–714.
  • 17. Zeng F, Wei H, Yeoh E, et al. Inflammatory markers of CRP, IL6, TNFalpha, and soluble TNFR2 and the risk of ovarian cancer: a meta-analysis of prospective studies. Cancer Epidemiol Biomark Prev. 2016;25(8):1231–1239.
  • 18. Brower V. Feeding the flame: new research adds to role of inflammation in cancer development. J Natl Cancer Inst. 2005;97(4):251–253.
  • 19. Milne K, Alexander C, Webb JR, et al. Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med. 2012; 10:33.
  • 20. Williams KA, Intidhar LG , Terry KL, et al. Prognostic significance and predictors of the neutrophil-tolymphocyteratio in ovarian cancer. Gynecologic Oncol. 2014;132(3):542–550.
  • 21. Yuan-qiu Wang , Chu Jin , Hua-min Zheng, et al.A novel prognostic inflammation score predicts outcomes in patients with ovarian cancer. Clinica Chimica Acta 456 (2016) 163–169.
  • 22. Xinming Yin, Ling Wub , Hui Yang, HongBo Yang. Prognostic significance of neutrophil–lymphocyte ratio (NLR) in patients with ovarian cancer A systematic review and meta-analysis. Medicine (Baltimore) 2019 Nov;98(45):e17475.
  • 23. Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated inepithelial ovarian cancer and predicts survival after treatment. CancerImmunol Immunother. 2009;58(1):15–23.
  • 24. Asher V, Lee J, Innamaa A, Bali A, et al. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Translat Oncol. 2011;13(7):499. Raungkaewmanee S, et al. Platelet to lymphocyte ratio as a prognostic fact.
  • 25. Zhang W-w, Liu K-j , Hu G-l , Wei-jiang Liang W-l, et al. Preoperative platelet/lymphocyte ratio is a superiorprognostic factor compared to other systemic inflammatory responsemarkers in ovarian cancer patients. Tumor Biol. 2015;36(11):8831–8837.
  • 26.Chuan Tian, Wei Song, Xia Tian , Yong Sun.Prognostic significance of platelet-to-lymphocyte ratio in patients with ovarian cancer: A meta-analysis.Eur J Clin Invest. 2018 May;48(5).
  • 27. Yubo Liu, Shengfu Chen, Chengyu Zheng, et al.The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer.BMC Cancer. 2017.
  • 28. Komura N, Mabuchi S, Shimura K, Kawano M, Matsumoto Y, Kimura T. Significance of Pretreatment C-Reactive Protein, Albumin, and C-Reactive Protein to Albumin Ratio in Predicting Poor Prognosis in Epithelial Ovarian Cancer Patients.Nutr Cancer. 2020 Aug 24:1-8.
  • 29. Peres LC, Mallen AR, Townsend MK, et al. High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium.Cancer Res. 2019 Oct 15;79(20):5442-5451.

Over kanserinde nötrofil/lenfosit, trombosit/lenfosit, CRP/Albümin oranları ile klinikopatolojik özellikler ve sağkalım arasındaki ilişki.

Yıl 2021, Cilt: 14 Sayı: 3, 666 - 674, 01.07.2021
https://doi.org/10.31362/patd.907695

Öz

Amaç: Over kanseri jinekolojik kanserler arasında en yüksek ölüm oranına sahip olan kanserdir.İnflamasyon temelli skorlar olan nötrofil lenfosit oranı (NLR), trombosit lenfosit oranı (PLR), CRP albümin oranı (CRP/Alb) çoğu kanserde prognoz üzerine etkisi gösterilmiştir. Biz de bu çalışmada NLR, PLR, CRP/Albümin oranlarının over kanserinin prognozu üzerine olan etkisini değerlendirmeyi amaçladık.

Gereç ve Yöntem: Çalışmamıza Eylül 2014 - Aralık 2020 tarihleri arasında Pamukkale Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı polikliniğine başvuran over karsinom tanılı 124 hasta çalışmaya alındı. Evre 1-4 arasında değişen toplam 124 hasta hasta çalışmaya dahil edildi. NLR, PLR, CRP/Albumin kesme noktaları ROC analizi ile yapıldı.


Bulgular: Hastalarımızın medyan yaşı 56 (sınırlar 24-84 ) idi. NLR oranı 63 hastada (%50), PLR oranı 56 hastada (%45), CRP/Alb oranı 61 hastada (%49) kesme değerine göre yüksek saptandı. PLR değeri ile progresyon sağkalım arasında istatistiksel olarak anlamlı ilişki yokken, genel sağkalımla istatistiksel olarak anlamlı ilişki bulunmaktaydı (p=0.01). PLR değeri yüksek olanlarda medyan genel sağkalım 23 ay iken PLR değeri düşük olanlarda 45 aydır olarak saptandı. CRP/Alb oranının ise hem progresyonsuz sağkalım hem de genel sağkalım ile istatistiksel olarak anlamlı ilişkisi mevcuttu (p=0.011; p=0.008). CRP/Alb değeri düşük olanlarda daha uzun progresyonsuz sağkalım ve genel sağkalım olduğu saptandı.


Sonuç: Diğer kanser tiplerinde olduğu gibi over kanserinde de inflamasyon belirteçlerinin kanser progresyonu üzerine dolayısıyla prognoza olan etkisi dikkat çekmektedir. PLR oranının genel sağkalımla, CRP/alb oranının ise hem genel sağkalım hemde progresyonsuz sağkalımla istatistiksel olarak anlamlı bir ilişkisi olduğunu gösterdik. Bu oranların gelecekte farklı tedavi gruplarını oluştururken hastaların seçiminde yardımcı olabileceği kanısındayız.

Kaynakça

  • 1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013;63(1):11–30.
  • 2. Morgan Jr RJ, Armstrong DK, Alvarez RD, et al. Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14(9):1134–63.
  • 3. Holschneider, C.H. and J.S. Berek. Ovarian cancer: epidemiology, biology, and prognostic factors. In seminars in surgical oncology. 2000. Wiley Online Library
  • 4. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol. 2004;191(3):733–740.
  • 5. Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol 2013;25:50–1.
  • 6. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–545.
  • 7. Nie W, Yu T, Sang Y, et al. Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment. Biochem Biophys Res Commun 2017;482:1400–1406.
  • 8. He W, Yin C, Guo G, et al. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol 2013; 30:439.
  • 9. Jung MR, Park YK, Jeong O, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 2011;104:504–10.
  • 10. Liu X, Qu JK, Zhang J, et al. Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: a meta-analysis. Medicine 2017;96:e8101.
  • 11. Gu XB, Tian T, Tian XJ, et al. Prognostic significance of neutrophil-tolymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep 2015;5:12493.
  • 12. Yodying H, Matsuda A, Miyashita M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2016;23:646–654.
  • 13. Baert T, Van Camp J, Vanbrabant L, et al. Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol Oncol 2018;150:31–37.
  • 14. Zhu Y, Zhou S, Liu Y, et al. Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review. BMC Cancer 2018;18:443.
  • 15. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005;117(2):104–111.
  • 16. Hefler LA, Concin N, Hofstetter G, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008;14(3):710–714.
  • 17. Zeng F, Wei H, Yeoh E, et al. Inflammatory markers of CRP, IL6, TNFalpha, and soluble TNFR2 and the risk of ovarian cancer: a meta-analysis of prospective studies. Cancer Epidemiol Biomark Prev. 2016;25(8):1231–1239.
  • 18. Brower V. Feeding the flame: new research adds to role of inflammation in cancer development. J Natl Cancer Inst. 2005;97(4):251–253.
  • 19. Milne K, Alexander C, Webb JR, et al. Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med. 2012; 10:33.
  • 20. Williams KA, Intidhar LG , Terry KL, et al. Prognostic significance and predictors of the neutrophil-tolymphocyteratio in ovarian cancer. Gynecologic Oncol. 2014;132(3):542–550.
  • 21. Yuan-qiu Wang , Chu Jin , Hua-min Zheng, et al.A novel prognostic inflammation score predicts outcomes in patients with ovarian cancer. Clinica Chimica Acta 456 (2016) 163–169.
  • 22. Xinming Yin, Ling Wub , Hui Yang, HongBo Yang. Prognostic significance of neutrophil–lymphocyte ratio (NLR) in patients with ovarian cancer A systematic review and meta-analysis. Medicine (Baltimore) 2019 Nov;98(45):e17475.
  • 23. Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated inepithelial ovarian cancer and predicts survival after treatment. CancerImmunol Immunother. 2009;58(1):15–23.
  • 24. Asher V, Lee J, Innamaa A, Bali A, et al. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Translat Oncol. 2011;13(7):499. Raungkaewmanee S, et al. Platelet to lymphocyte ratio as a prognostic fact.
  • 25. Zhang W-w, Liu K-j , Hu G-l , Wei-jiang Liang W-l, et al. Preoperative platelet/lymphocyte ratio is a superiorprognostic factor compared to other systemic inflammatory responsemarkers in ovarian cancer patients. Tumor Biol. 2015;36(11):8831–8837.
  • 26.Chuan Tian, Wei Song, Xia Tian , Yong Sun.Prognostic significance of platelet-to-lymphocyte ratio in patients with ovarian cancer: A meta-analysis.Eur J Clin Invest. 2018 May;48(5).
  • 27. Yubo Liu, Shengfu Chen, Chengyu Zheng, et al.The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer.BMC Cancer. 2017.
  • 28. Komura N, Mabuchi S, Shimura K, Kawano M, Matsumoto Y, Kimura T. Significance of Pretreatment C-Reactive Protein, Albumin, and C-Reactive Protein to Albumin Ratio in Predicting Poor Prognosis in Epithelial Ovarian Cancer Patients.Nutr Cancer. 2020 Aug 24:1-8.
  • 29. Peres LC, Mallen AR, Townsend MK, et al. High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium.Cancer Res. 2019 Oct 15;79(20):5442-5451.
Toplam 29 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Onkoloji ve Karsinogenez
Bölüm Araştırma Makalesi
Yazarlar

Burcu Yapar Taşköylü 0000-0003-4755-2753

Esin Avcı 0000-0002-9173-0142

Atike Gökçen Demiray 0000-0003-4397-5468

Serkan Değirmencioğlu 0000-0002-1213-2778

Gamze Gokoz Dogu

Arzu Yaren

Ahmet Ergin 0000-0001-5236-7507

Derya Kılıç 0000-0001-8003-9586

Canan Karan Bu kişi benim 0000-0002-1293-2046

Burçin Çakan Demirel Bu kişi benim 0000-0003-0734-0692

Tolga Doğan Bu kişi benim 0000-0003-1281-942X

Melek Özdemir 0000-0003-1894-9743

Yayımlanma Tarihi 1 Temmuz 2021
Gönderilme Tarihi 2 Nisan 2021
Kabul Tarihi 3 Mayıs 2021
Yayımlandığı Sayı Yıl 2021 Cilt: 14 Sayı: 3

Kaynak Göster

AMA Yapar Taşköylü B, Avcı E, Demiray AG, Değirmencioğlu S, Gokoz Dogu G, Yaren A, Ergin A, Kılıç D, Karan C, Çakan Demirel B, Doğan T, Özdemir M. Over kanserinde nötrofil/lenfosit, trombosit/lenfosit, CRP/Albümin oranları ile klinikopatolojik özellikler ve sağkalım arasındaki ilişki. Pam Tıp Derg. Temmuz 2021;14(3):666-674. doi:10.31362/patd.907695
Creative Commons Lisansı
Pamukkale Tıp Dergisi, Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı ile lisanslanmıştır